In a patient with acute ischemic stroke treated with tissue plasminogen activator (tPA) who now has a 170 mL psoas hematoma, anemia, and thrombocytopenia, what is the appropriate management?

Management of Post-tPA Psoas Hematoma with Anemia and Thrombocytopenia

Immediately discontinue any remaining tPA infusion, obtain emergent imaging to assess hematoma stability, send stat labs (CBC, coagulation panel, fibrinogen, type and crossmatch), and administer cryoprecipitate (10 units) plus platelets (6-8 units) to reverse the fibrinolytic state and correct thrombocytopenia. 1

Immediate Hemorrhage Control

Stop all thrombolytic therapy immediately if any tPA infusion is still running. 1

• Administer cryoprecipitate containing factor VIII to rapidly correct the systemic fibrinolytic state created by tPA—the recommended dose is sufficient to restore fibrinogen levels (typically 10 units). 1

• Transfuse platelets (6-8 units) to address thrombocytopenia and improve hemostasis, as platelet dysfunction contributes significantly to bleeding risk after thrombolysis. 1

• Obtain emergent CT imaging of the abdomen/pelvis to assess current hematoma size, active extravasation, and any expansion from the initial 170 mL volume. 1

Laboratory Assessment

Send stat complete blood count, PT/PTT/INR, fibrinogen level, type and screen to quantify the degree of anemia and thrombocytopenia and guide transfusion therapy. 1

• The fibrinogen level is critical as tPA depletes fibrinogen, and levels below 150-200 mg/dL significantly impair clot formation. 1

• Serial hemoglobin measurements every 4-6 hours initially to monitor for ongoing bleeding. 1

Transfusion Strategy

Transfuse packed red blood cells to maintain hemoglobin >7-8 g/dL, with higher targets (>9 g/dL) reasonable given acute stroke and need for adequate cerebral perfusion. 1

• Platelet transfusion threshold: Given active bleeding (psoas hematoma), transfuse to maintain platelets >50,000/mm³, ideally >75,000/mm³. 1

• While thrombocytopenia <100,000/mm³ is typically considered a contraindication to tPA, the patient has already received it—now the priority is hemorrhage control, not stroke treatment eligibility. 2, 3

Withhold Antithrombotic Therapy

Do not administer aspirin or any antiplatelet agents for at least 24 hours after tPA administration, and longer in the setting of active hemorrhage. 1

• Avoid therapeutic anticoagulation (heparin, LMWH) given the active bleeding complication. 1

• Once hemorrhage is controlled and stabilized (typically 24-48 hours), aspirin 160-325 mg daily can be cautiously reintroduced for stroke secondary prevention. 1

Surgical Consultation

Obtain urgent vascular surgery or interventional radiology consultation to evaluate for potential intervention if the hematoma is expanding or causing hemodynamic instability. 1

• A 170 mL psoas hematoma is substantial but may be managed conservatively if stable. 1

• Indications for intervention include: ongoing hemodynamic instability despite resuscitation, evidence of active arterial extravasation on CT angiography, or compartment syndrome. 1

Monitoring and Supportive Care

Admit to intensive care unit for close hemodynamic monitoring, serial neurological examinations, and laboratory surveillance. 1

• Monitor for signs of hematoma expansion: increasing abdominal/flank pain, hip flexion weakness, femoral nerve compression symptoms (numbness in anterior thigh). 1

• Serial neurological assessments every 1-2 hours initially to detect any worsening stroke symptoms or new intracranial hemorrhage. 1

• Maintain strict blood pressure control per post-tPA protocols: systolic <180 mmHg and diastolic <105 mmHg to minimize risk of intracranial hemorrhage while ensuring adequate perfusion. 1

VTE Prophylaxis Considerations

Delay pharmacologic VTE prophylaxis until hemorrhage is controlled and stable, typically 48-72 hours after bleeding cessation. 1

• Use intermittent pneumatic compression devices for mechanical VTE prophylaxis in the interim, as these do not increase bleeding risk. 1

• Once bleeding is controlled (stable hemoglobin, no hematoma expansion for 24-48 hours), initiate prophylactic-dose LMWH or unfractionated heparin for stroke-related immobility. 1

Common Pitfalls

The most critical error is failing to rapidly reverse the fibrinolytic state with cryoprecipitate—this is the specific antidote for tPA-induced coagulopathy and must be given immediately. 1

• Do not wait for fibrinogen levels before administering cryoprecipitate if there is clinical evidence of significant hemorrhage. 1

• Avoid premature aspirin administration—while aspirin is recommended within 24-48 hours post-stroke, active hemorrhage is an absolute contraindication. 1

• The combination of post-tPA hemorrhage plus thrombocytopenia creates exceptionally high bleeding risk; aggressive correction of both the fibrinolytic state and platelet count is essential. 1, 2, 3